APRETUDE: the first and only long-acting injectable PrEP option
*HPTN 083 (N=4566) was a randomized, double-blind, active-controlled noninferiority trial of the safety and efficacy of APRETUDE compared with daily oral TDF/FTC for HIV-1 prevention in HIV-1–uninfected men and transgender women who have sex with men and who have evidence of high-risk behavior for HIV-1 infection. The primary endpoint was rate of incident HIV-1 infection. The trial included the prespecified ability to test for superiority of APRETUDE over TDF/FTC.1
†HPTN 084 (N=3224) was a randomized, double-blind, active-controlled superiority trial of the safety and efficacy of APRETUDE compared with daily oral TDF/FTC for HIV-1 prevention in adult, uninfected, cisgender women at risk of acquiring HIV-1. The primary endpoint was rate of incident HIV-1 infection.2
‡After optional oral lead-in and initiation injections.
HPTN=HIV Prevention Trials Network; PrEP=pre-exposure prophylaxis; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.
"With CABENUVA injections, I feel a sense of independence from not having to take a pill at the same time every day and fearing that I missed it.
Instead of stressing about daily treatment, I can focus on treatment once a month. Even though it's just a few seconds a day to take a pill, I now don't have to remember to take my HIV treatment until my next appointment."
— Mark, clinical trial participant and patient ambassador
Patient experiences with CABENUVA after receiving 1 month of oral lead-in of cabotegravir and rilpivirine. Individual patient experiences are not indicative of all patient experiences or clinical trial results.
You may also be interested in


For your medical practice
CBTWCNT230013